Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Total Liabilities (2016 - 2025)

Tvardi Therapeutics' Total Liabilities history spans 13 years, with the latest figure at $11.1 million for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 72.75% to $11.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.1 million, a 72.75% decrease, with the full-year FY2025 number at $11.1 million, down 72.75% from a year prior.
  • Total Liabilities hit $11.1 million in Q4 2025 for Tvardi Therapeutics, roughly flat from $11.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for TVRD hit a ceiling of $68.8 million in Q4 2023 and a floor of $10.8 million in Q2 2025.
  • Historically, Total Liabilities has averaged $30.1 million across 5 years, with a median of $22.8 million in 2022.
  • Biggest five-year swings in Total Liabilities: soared 261.53% in 2024 and later tumbled 82.23% in 2025.
  • Tracing TVRD's Total Liabilities over 5 years: stood at $19.5 million in 2021, then rose by 20.09% to $23.5 million in 2022, then soared by 193.12% to $68.8 million in 2023, then tumbled by 40.62% to $40.8 million in 2024, then plummeted by 72.75% to $11.1 million in 2025.
  • Business Quant data shows Total Liabilities for TVRD at $11.1 million in Q4 2025, $11.2 million in Q3 2025, and $10.8 million in Q2 2025.